Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343678 | 0.92 | TGFBR1 (0.51) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL4339418 | 0.89 | TGFBR1 (0.49) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL4350435 | 0.89 | TGFBR1 (0.49) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL30194941 | 0.84 | TGFBR1 (0.86) | TGFBR1MAPK14RIPK2ACVR1B | |
| SCHEMBL376161 | 0.84 | TGFBR1 (0.86) | TGFBR1MAPK14RIPK2ACVR1B | |
| SCHEMBL4350318 | 0.83 | TGFBR1 (0.55) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL4336656 | 0.79 | TGFBR1 (0.56) | TGFBR1MAPK14 | |
| SCHEMBL4344472 | 0.79 | TGFBR1 (0.54) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL4339710 | 0.76 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2ACVR1B | |
| SCHEMBL29504100 | 0.76 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2ACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612094-B2 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2009-11-03 | — | — | US | claimed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN MA INC. | 2006-03-23 | — | — | US | claimed |
| EP-1499308-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2003087304-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | ALK, ACVR1, ACVRL1 | TGFBR1 13/4885MAPK14 3383/4885KDR 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.